Clinical Trial: Paclitaxel, Carboplatin, and Oral Etoposide Followed by Weekly Paclitaxel in High Grade Neuroendocrine Carcinoma

Study Status: Completed
Recruit Status: Completed
Study Type: Interventional

Official Title: Phase II Study of Paclitaxel, Carboplatin, and Oral Etoposide Followed by Weekly Paclitaxel in the Treatment of High Grade Neuroendocrine Carcinoma

Brief Summary: carboplatin and etoposide, followed by maintenance therapy with weekly paclitaxel in patients with poorly differentiated neuroendocrine carcinomas. We hope to identify a "standard treatment" for this unusual group of patients who are not usually eligible for clinical trials.

Detailed Summary:

Upon determination of eligibility, patients will be receive:

  • Paclitaxel + Carboplatin + Etoposide

Sponsor: SCRI Development Innovations, LLC

Current Primary Outcome: Overall response

Original Primary Outcome: Same as current

Current Secondary Outcome:

  • Overall survival
  • Time to progression
  • Overall toxicity


Original Secondary Outcome: Same as current

Information By: SCRI Development Innovations, LLC

Dates:
Date Received: September 12, 2005
Date Started: December 1998
Date Completion:
Last Updated: June 28, 2010
Last Verified: October 2008